“The apprehension with employing non IID shown ingredients is justified as it is actually unachievable To guage if FDA would discover the ‘novel excipient’ Risk-free to be used in a drug products as there's no described course of action for evaluation and acceptance of excipients. The FDA steerage on ‘Nonclinical Reports for the protection